Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The North America glioma market was valued at USD 1.03 Billion in 2025. It is expected to grow at a CAGR of 3.22% during the forecast period of 2026-2035, reaching USD 1.41 Billion by 2035. The market is driven by the rising incidence of brain tumors in the region, growing regulatory approvals of innovative glioma therapies, and increasing adoption of advanced diagnostic techniques.
Latest News on the North America Glioma Market (2026)
-
According to the American Society of Clinical Oncology (ASCO), approximately 24,820 adults are expected to be diagnosed with primary cancerous brain and spinal cord tumors in the United States annually, driving demand for advanced glioma treatment options.
-
In August 2024, the United States Food and Drug Administration (FDA) accepted and granted priority review to Servier Pharmaceuticals' vorasidenib, a novel dual inhibitor targeting IDH-mutant glioma, expanding the treatment pipeline.
-
The key market players play a crucial role by investing in research and development, expanding therapeutic pipelines, improving diagnostic solutions, and forming strategic collaborations, thereby accelerating innovation, enhancing treatment accessibility, and supporting overall market growth.
Key Market Trends and Insights
- By type, the glioblastoma segment likely accounted for approximately 45% of the market share in the historical period.
- By diagnosis, the magnetic resonance imaging (MRI) segment is expected to lead the market in the forecast period.
- By treatment type, the chemotherapy segment is anticipated to dominate the market in the historical period.
Market Size and Forecast
- Market Size (2025): USD 1.03 Billion
- Projected Market Size (2035): USD 1.41 Billion
- CAGR (2026-2035): 3.22%
Compound Annual Growth Rate
3.22%
Value in USD Billion
2026-2035
North America Glioma Market Overview
Glioma is a primary brain tumor originating from glial cells, encompassing subtypes such as astrocytoma, oligodendroglioma, and glioblastoma multiforme. As per Expert Market Research (EMR), the market was valued at USD 1.03 Billion in 2025. The region holds a dominant position due to its advanced healthcare infrastructure, high research and development investment, and strong regulatory frameworks that accelerate the approval of new therapies. Diagnostic advancements, including magnetic resonance imaging (MRI) and molecular profiling, and the rising adoption of temozolomide chemotherapy and radiation therapy are collectively shaping the region's market landscape.
North America Glioma Market Growth Drivers
Rising Incidence of Glioblastoma to Fuel the Market Demand
The escalating burden of glioblastoma multiforme and other high-grade brain tumors is a primary driver of the market. According to Quinn T Ostrom et al., 2023, gliomas accounted for 26.3% of all primary brain and central nervous system tumors, with glioblastoma representing the most common malignant subtype. The substantial mortality and low survival rates associated with these tumors emphasize the urgent need for advanced therapies, thereby accelerating research, innovation, and overall market expansion.
North America Glioma Market Growth Trends
The key trends in the market include an increase in regulatory approvals, driving faster commercialization of novel therapies and improving patient access to advanced neuro-oncology treatments.
Growing Regulatory Approvals to Accelerate the Market Landscape
The surge in regulatory approvals of novel, targeted glioma treatment agents, is a key trend shaping the market. In February 2024, the FDA granted priority review to vorasidenib, a dual IDH-mutant glioma inhibitor developed by Servier Pharmaceuticals, based on positive Phase 3 INDIGO trial findings, marking a significant step in precision oncology for diffuse glioma. Additionally, in April 2024, the FDA approved OJEMDA (tovorafenib) for relapsed or refractory BRAF-altered pediatric low-grade glioma, representing the first approval for this molecular subtype. These approvals are among the key trends driving the market.
North America Glioma Market Segmentation
Market Breakup by Type
- Astrocytoma
- Oligodendroglioma
- Glioblastoma
Market Breakup by Diagnosis
- Angiograms
- Magnetic Resonance Imaging (MRI)
- Computerized Tomography (CT)
- Surgical Biopsy
- Others
Market Breakup by Treatment Type
- Chemotherapy
- Radiation
- Surgery
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by Country
- United States
- Canada
North America Glioma Market Share
Glioblastoma Segment Expected to Lead the Market Share by Type
The glioblastoma segment is likely to hold a significant share in the market by type, owing to its status as the most prevalent and aggressive form of primary brain tumor. Its high recurrence rate and limited treatment response drive significant and sustained clinical expenditure on chemotherapy protocols, including temozolomide, radiation therapy, and surgical resection, reinforcing the segment's continued market leadership through the forecast period.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
North America Glioma Market Analysis by Region
The regions included in the market are the United States and Canada. Among these, the United States is anticipated to hold a substantial share in the market, supported by advanced glioma diagnosis infrastructure, high R&D investment, and a robust pipeline of novel brain cancer treatment agents. Canada also contributes significantly to the regional market, driven by a large number of glioblastoma diagnoses and growing public investment in neuro-oncology research.
Leading Players in the North America Glioma Market
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer Inc.
Pfizer Inc. is a global pharmaceutical leader headquartered in New York, United States. The company maintains an active oncology pipeline with research in brain tumors treatment and neurological conditions. Pfizer leverages its strong R&D capabilities, broad clinical trial network, and global commercialization infrastructure to develop and deliver targeted therapies addressing high unmet needs in neuro-oncology, including glioblastoma multiforme.
Novartis AG
Novartis AG is a Switzerland-based multinational pharmaceutical company with a significant presence in oncology. The company invests extensively in glioma treatment research, pursuing targeted molecular therapies and combination regimens for brain cancer. Novartis's established regulatory expertise, global manufacturing capabilities, and strong clinical development programs position it as a key contributor to the North America glioma treatment landscape.
Johnson & Johnson
Johnson and Johnson is a diversified healthcare conglomerate headquartered in the United States. Through its Janssen Pharmaceuticals division, the company focuses on oncology innovation, including research into brain tumor therapy and neuro-oncology solutions. Its integrated approach combining pharmaceuticals, medical devices, and diagnostics supports a broad strategy for advancing glioma diagnosis and treatment across North American healthcare systems.
Merck & Co., Inc.
Merck & Co Inc. is a United States-based science and technology company with significant oncology expertise. The company leverages strategic collaborations and pipeline development to accelerate the market entry of novel brain cancer treatment candidates, including those targeting IDH-mutant glioma. Merck's prescription product portfolio and commitment to immunotherapy research reinforce its position in the North America glioma market.
Other players in the market include Roche Holding AG, Bristol-Myers Squibb Company, Amgen Inc., AstraZeneca PLC, AbbVie Inc., and Eli Lilly and Company.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Key Questions Answered in the North America Glioma Market Report
- What was the North America glioma market value in 2025?
- What is the North America glioma market forecast outlook for 2026-2035?
- What major factors aid the demand for the North America glioma market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major North America glioma market trends?
- Which drug class is expected to dominate the market segment?
- Which formulation is projected to lead the market segment?
- Which packaging type is anticipated to drive the market segment?
- Which distribution channel is likely to dominate the market segment?
- Who are the key players in the North America glioma market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$2699 $2429
-
$4299 $3869
-
$5799 $4949
-
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Diagnosis |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
